<DOC>
	<DOC>NCT00888719</DOC>
	<brief_summary>Objective of the trial is to assess dose-dependency, efficacy and safety and to estimate optimum dosage for confirmatory study of CWP-0403 50mg, 100mg given twice daily for 12 weeks to type 2 diabetes patients who are insufficiently controlled by diet and exercise in comparison to placebo.</brief_summary>
	<brief_title>Therapeutic Exploratory Study of CWP-0403</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Age of≥25 and &lt;75 with typeⅡ DM patients Patients whose level of HbA1c is over 7.0% and less than 10% within 4weeks of screening registration In spite of dietary and exercise treatment over 8weeks, the level of HbA1c is over 6.5% and less than 10%. BMI between 20kg/㎡ and 40kg/㎡ Out patients patients who agree the trial participation with written informed consent TypeⅠDM, Gestational diabetes. Patients who are being treated with insulin Fasting glucose level over 250mg/dL Patients who are not compliant with dietary and exercise treatment during 8 weeks of screening period. (Evaluated "Bad" and worse) Severe hepatic dysfunctions (i.e.: uncompensated hepatic cirrhosis)or AST or ALT level over 2.5times as high as UNL on screening visit. Severe renal dysfunctions (i.e.: renal failure) or serum creatinine level over 1.5mg/dl Severe cardiac dysfunction(i.e.: heart failure ) or history of myocardial infarction within 6months of screening Chronic pulmonary disease or pulmonary infarction Pancreatitis patients Patients who are being treated for life threatening disease such as cancer, severe trauma or infection. Uncontrollable diabetic complications(neuropathy, retinopathy, nephrosis) Severe ketosis or experience of diabetic coma Intestinal disease affecting digestion or absorption or history of GI dissection surgery except for appendectomy. Pregnant, expecting to be pregnant or nursing female Excessive alcohol consumption (Over 80g of alcohol/day: Over 1 bottle of 360ml Soju/day) Participants of other clinical trials within 3 months of screening Patients medicated with following nonconcomitant medications Insulins or oral antidiabetics Oral (for more than 1 week) or IV corticosteroids (External and inhaled corticosteroids excluded) appetite suppressant exenatide or other GLP1 analogues Other medications in development Hypersensitive or intolerance to DPP4 inhibitory patients who are decided to be inappropriate for this trial subject by the investigators</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>